Suven Life Sciences Limited has responded to surveillance queries from both BSE and NSE regarding unusual price and volume movements in its stock, clarifying that no material events are pending disclosure that could justify the recent market activity.

Exchange Surveillance Response

The Hyderabad-based pharmaceutical company issued its clarification on April 8, 2026, in response to surveillance emails received from both exchanges on April 7, 2026. The company addressed specific reference numbers from both exchanges regarding the price movement concerns.

Company's Position on Price Movement

Suven Life Sciences emphasized its compliance with disclosure requirements, stating it has been regularly notifying stock exchanges of all events and information falling under SEBI LODR Regulation 30. The company confirmed it currently has no material announcements or events due for notification that could influence its stock's price or volume behavior.

The management attributed the recent price and volume movements to market speculation, declining to provide additional commentary on the development. This response indicates the company believes the stock movement is not based on any fundamental business developments or undisclosed material information.

Regulatory Compliance Framework

The company reiterated its commitment to transparency by confirming regular compliance with SEBI LODR Regulation 30, which mandates disclosure of material events and information that could impact stock performance. The clarification document was signed by Company Secretary K. Sangeetha Laxmi and has been made available on both exchange websites and the company's official website for public information.

Corporate Communication

The formal response demonstrates Suven Life Sciences' proactive approach to addressing market surveillance concerns and maintaining regulatory compliance. The company requested both exchanges to disseminate the clarification on their websites while simultaneously uploading the information on its corporate website to ensure broad accessibility for investors and stakeholders.

Suven Life Sciences Limited has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026, to both major stock exchanges. The pharmaceutical company filed the mandatory certificate on April 06, 2026, demonstrating its commitment to regulatory compliance.

Regulatory Filing Details

The company submitted the certificate to both BSE Limited and National Stock Exchange of India Limited, fulfilling its obligations under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018. The filing was signed by K Sangeetha Laxmi, Company Secretary, on behalf of Suven Life Sciences Limited.

Registrar Confirmation

Kfin Technologies Limited, serving as the Registrar and Share Transfer Agent for Suven Life Sciences Limited, issued certificates dated April 01, 2026. The certificates were addressed to both Central Depository Services (India) Limited and National Securities Depository Limited, confirming compliance with regulatory requirements.

C Shobha Anand, Vice President at Kfin Technologies Limited, signed the certificates confirming that:

• Details of securities dematerialized and rematerialized during the quarter have been properly documented
• All required information has been furnished to stock exchanges where the company's shares are listed
• The company has met its obligations under SEBI regulations

Corporate Information

Suven Life Sciences Limited operates from its registered office located at 8-2-334 I SDE Serene Chambers, 6th Floor Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500 034, Telangana. The company maintains investor communication through its dedicated email and website channels.

Compliance Significance

This quarterly filing represents a standard regulatory requirement under SEBI's framework for depositories and participants. The certificate ensures transparency in the dematerialization and rematerialization process of securities, providing stakeholders with confidence in the proper handling of share transactions during the quarter ended March 31, 2026.